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ABSTRACT
Background
Non-Hodgkin’s lymphomas are a heterogeneous group of neoplasms arising from the lymphopoi-
etic system including a wide range of subtypes of either B-cell or T-cell lymphomas. The few
established risk factors for the development of these neoplasms include viral infections and
immunological abnormalities, but their etiology remains largely unknown. Evidence suggests that
certain medical conditions may be linked, through immunosuppression, to the risk of non-
Hodgkin’s lymphoma. Multiple myeloma is a neoplasm of plasma cells that accounts for approx-
imately 15% of lymphopoietic cancers. Increases in the incidence of non-Hodgkin’s lymphoma
and multiple myeloma in the past  implicate environmental factors as potential causal agents.
Design and Methods
In the European Prospective Investigation into Cancer and Nutrition (EPIC), 1,213 histologically
confirmed incident cases of non-Hodgkin’s lymphoma and multiple myeloma (594 men; 619
women) were identified during a follow-up of 8.5 years. Cox proportional hazard models were
used to explore the association between self-reported diabetes, diagnosed after 30 years of age,
and the risk of non-Hodgkin’s lymphoma overall and multiple myeloma and various lymphoma
subtypes.
Results
We found no association between a personal history of diabetes and the risk of non-Hodgkin’s
lymphoma overall in men (HR: 1.28, 95% CI: 0.89-1.84), in women (HR: 0.71, 95% CI: 0.41-
1.24), or in men and women combined (HR: 1.09, 95% CI: 0.80-1.47). Among the B-non-
Hodgkin’s lymphoma subtypes, we observed a statistically significant increased risk of B-cell
chronic lymphocytic leukemia (HR: 2.0, 95% CI: 1.04-3.86) in men, but not in women (HR: 1.07,
95% CI: 0.33-3.43).
Conclusions
This prospective study did not provide evidence for a role of self-reported diabetes in the etiolo-
gy of non-Hodgkin’s lymphoma overall or multiple myeloma. We found an increased risk of B-cell
chronic lymphocytic leukemia among men with diabetes, but not among women. We hypothesize
that diabetes may not play a causal role in the etiology of B-cell chronic lymphocytic leukemia,
though the underlying pathogenic mechanisms of both disorders may include shared genetic,
host and/or environmental susceptibility factors.
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Introduction
Non-Hodgkin’s lymphomas (NHL) are a heteroge-
neous group of B-cell or T-cell neoplasms that originate
from lymphoid tissues. As a group they are the seventh
most commonly diagnosed cancer in Europe, but their
etiology still remains largely unknown. In 2004,
approximately 121,200 cases of NHL were diagnosed
in Europe, causing an estimated 65,200 deaths.1 The
incidence of NHL rose significantly between the 1970s
and 1980s, mainly in Western countries, and reached a
plateau during the 1990s.2 A part of this increase is
attributed to improved cancer reporting, changes in
lymphoma classification, better means of diagnosis and
an increase in AIDS-associated lymphoma, while other
factors remain elusive. Multiple myeloma (MM) is a
neoplasm of plasma cells that accounts for approxi-
mately 15% of lymphopoietic cancers.3 Increases in the
incidence of MM in the past implicate environmental
factors as potential causal agents.4
The strongest risk factors for NHL include rare condi-
tions entailing severe immune suppression, such as
hereditary and acquired immunodeficiency syndromes,
in which risk is about 10 to 100 times higher than that
of the general population.5 Epstein-Barr virus (EBV),
Helicobacter pylori, human T-cell lymphotropic virus-1
(HTLV), hepatitis C virus and, more recently, hepatitis
B virus are pathogens that have been linked to an
increased risk of NHL. Use of various medications such
as oral contraceptives, estrogen replacement therapy,
anti-convulsant drugs, and various steroids6,7 have also
been suggested to be associated with NHL. Recent evi-
dence suggests that dietary or lifestyle habits, such as
smoking and alcohol consumption, might also modify
the risk of NHL. Factors that have been associated with
MM include high doses of ionizing radiation, and occu-
pational exposure in farming and petrochemical indus-
tries.8 The role of chronic antigenic stimulation in the
etiology of MM has also been investigated.8
In addition, as possible conditions predisposing to
NHL, autoimmune and inflammatory conditions, such
as systemic lupus erythematosus, rheumatoid arthritis,
celiac disease and Sjőgren’s syndrome, have been
observed to increase the risk of NHL in a number of
studies,9,10 while psoriasis and inflammatory bowel dis-
orders have not been consistently associated. These
diseases are characterized by dysregulated lymphocyte
reactivity against self-antigens and the production of
autoantibodies.9 Some researchers have hypothesized
that the ongoing abnormal lymphocyte activation in
immunosuppressed states could predispose to NHL.  
Diabetes is a common, increasing frequent health
condition associated with a wide range of metabolic,
immunological, and hormonal aberrations.11 Recent
observations indicate that autoimmunity plays a role in
type 2 diabetes.12 This condition has been described as
an acute-phase disease of the innate immune system, in
which oversecretion of cytokines may contribute to the
development of insulin resistance and impairment of
insulin secretion in pancreatic β-cells.12 Approximately
135 million people worldwide are affected  by type 2
diabetes and the number of adults with diabetes in the
world is expected to rise to at least 300 million by 2025,
making it a serious public health concern.13 An
increased risk of cancer, in particular pancreatic cancer,
liver cancer, breast cancer, MM, and cancer of the
endometrium among patients with diabetes has been
observed in several studies.11,14-16 The proposed biologi-
cal mechanism relates to insulin resistance, a prediag-
nostic stage of type 2 diabetes, and insulin-like growth
factors, both of which have been shown to stimulate
tumor cell proliferation in experiments.17-20
Epidemiological studies exploring the role of type 2
diabetes in the etiology of NHL have yielded inconsis-
tent results. Two of the four cohort studies found an
elevated risk of NHL5,11,21 among diabetic individuals.
Four population and hospital-based case-control stud-
ies also demonstrated positive associations,22-25 while
five others reported no or inverse associations.26-29 The
inconsistency of the findings to date may partly be
attributed to differences in study design, lack of infor-
mation on potential confounders, use of inappropriate
comparison populations and ascertainment of cases
from cancer or mortality registries. 
The aim of this study was to take advantage of a
large prospective study to evaluate the association
between a personal history of diabetes and the risk of
NHL and MM and various lymphoma subtypes in
Europe.
Design and Methods
The European Prospective Investigation into Cancer
and Nutrition (EPIC) is an ongoing multicenter prospec-
tive cohort study designed to investigate the relation
between nutritional status, lifestyle, and environmental
factors and the risk of cancer and other chronic dis-
eases. The cohort comprises 521,457 eligible partici-
pants from the general population, enrolled between
1992 and 2000, aged 20 years or above.  Participants
were recruited from 23 study centers in ten European
countries: Denmark (Aarhus and Copenhagen), France,
Germany (Heidelberg and Potsdam), Greece, Italy
(Florence, Varese, Naples, Ragusa and Turin), the
Netherlands (Bilthoven and Urecht), Norway, Spain
(Granada, Murcia, Asturias, Pamplona, and San
Sebastian with the co-ordination center in Barcelona),
Sweden (Malmo and Umea), and the United Kingdom
(Oxford and Cambridge). There were some exceptions
made in the French cohort, where recruitment was
based on female participants of a health insurance
agency for school and university employees; the
Utrecht cohort and Florence cohort, where female par-
ticipants were recruited from breast cancer screening
programs; the Ragusa cohort, based on blood donors
and their spouses; and most of the Oxford cohort,
where mainly vegetarian volunteers and healthy eaters
were recruited. Only women were enrolled in France,
Norway, Utrecht, and Naples. 
The study design and methods for collecting baseline
data have been described in detail elsewhere by Riboli
et al.30 All eligible participants provided written
informed consent. Approval for the EPIC study was
obtained from the ethical review boards of the
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International Agency for Research on Cancer (IARC)
and local participating centers.
Study population
Of the 521,457 eligible participants, we excluded par-
ticipants if they were prevalent cases of cancer at any
site at the time of enrolment, participants with missing
data on lifestyle and dietary questionnaire, or those
who were in the top or bottom 1% of the ratio of ener-
gy intake to estimated energy requirement, which was
calculated from body weight, height and age
(n=41,604). Participants were also excluded if they
were members of the French cohort because case ascer-
tainment was incomplete in France (n=69,426). We fur-
ther excluded 65 cases with Hodgkin’s disease and 29
uncertain lymphoma cases, as well as all participants
with missing data on diabetes (n=16,856). The current
analyses are related to a total of 393,477 EPIC partici-
pants and 1,213 incident cases of NHL (594 men, 619
women). 
Assessment of end-points
Incident lymphoma cases were identified through
population cancer registries in Denmark, Italy, the
Netherlands, Norway, Spain, Sweden, and the United
Kingdom, and through active follow-up in Germany and
Greece. Active follow-up methods included health insur-
ance records, cancer and pathology hospital registries,
and directly contacting participants or next of kin.
Mortality data were obtained from cancer or mortality
registries at the regional or national level. Follow-up
began at the date of recruitment and ended at either the
date of diagnosis of lymphoma, death or last complete
follow-up. Date of complete follow-up varied for the dif-
ferent study centers. Participants were censored as fol-
lows: December 2002 (Granada); December 2003
(Florence, Varese, Naples; Murcia; Bilthoven; Aarhus,
Copenhagen), December 2004 (Ragusa, Turin; Asturias,
Navarra; Cambridge, Oxford; Utrecht; Malmö;
Norway); June 2005 (Umeå); December 2005 (San
Sebastian). For Germany and Greece, the end of the fol-
low-up was considered to be the last known contact,
date of diagnosis, or date of death, whichever came first. 
Lymphoma cases were initially identified according
to the second revision of the International
Classification of Disease for Oncology (ICD-O-2). All
cases were subsequently recoded using the WHO clas-
sification system of tumors of hematopoietic and lym-
phoid tissue, which is based on ICD-O-3.31 The conver-
sion was made with the help of a web-based program
available from the SEER webpage and involved expert-
ise of a pathologist (TR) as well as experts from the
EPIC centers (see Appendix, and also a publication by
Morton et al.32). Cases in which ICD-O-2 codes could
not be translated unequivocally into a lymphoma diag-
nosis according to the WHO classification system were
categorized as lymphomas unclassified (“nos”).  
In the current analyses, we considered the following
subtypes of NHL: overall NHL including MM; within
NHL the B-cell lymphomas (B-NHL) and T-cell lym-
phomas (T-NHL), and among B-NHL the subtypes dif-
fuse large B-cell lymphomas, follicular lymphomas, B-
cell chronic lymphocytic leukemia (B-CLL) and MM.
Other rare subtypes were not considered because of
the small number of cases. 
Assessment of exposure
Information on socio-demographics, lifestyle charac-
teristics and medical history, were collected via ques-
tionnaire at the time of entry into the study. Diabetes
status was self-reported and was obtained through a
questionnaire in which participants were asked if they
had ever been diagnosed with ‘diabetes’ and if so, at
what age. No distinction was made between the types
of diabetes. However, it is likely that the vast majority
of them were type 2 diabetics, as most diagnoses were
made after the age of 30. Information on the use of
insulin treatment was also obtained at baseline through
a questionnaire. 
Detailed information was obtained on smoking sta-
tus (life-long non-smoker; current smoker <15 per day,
15-24 per day, >25 per day; past smoker <10 years; past
smoker >10 years; other smoker including pipes and
cigars), alcohol intake in grams per day (no ethanol, <5
grams per day, 5-14 grams per day, 15-29 grams per
day, >30 grams per day), level of education (no degree
or primary school, technical or professional school, sec-
ondary school, university degree), occupation, age at
puberty and reproductive history, use of contraception
and hormonal drugs, current illnesses and history of
previous illnesses including surgical operations.
Assessment of physical activity included household,
recreational and occupational activities. Average meta-
bolic equivalent-hours (MET-hr) were derived for recre-
ational and household activities, based on the types
and durations of activities reported separately for sum-
mer and winter. Physical activity was coded by cross-
classifying participants on the basis of sex-specific
quartiles of recreational and household activities and
categories of occupational activity, and was coded as
inactive, moderately inactive, moderately active and
active.  
Participants’ height and weight were measured at
baseline, except in Norway and Oxford, where self-
reported height and weight were obtained via ques-
tionnaire. Body mass index (BMI) was calculated as
weight in kilograms divided by height in squared
meters. BMI was split into categories using WHO cut-
off points33 as follows: underweight < 18.50, normal
18.50 – 24.99, overweight 25 – 29.99 and obese ≥30.
There were few underweight participants in the cohort
and therefore, ‘underweight’ and ‘normal’ categories
were collapsed and used as the reference group in both
men and women. Waist circumference was split into
two categories, according to the International Diabetes
Federation’s (IDF)34,35 definition of central obesity, using
ethnic-specific cut-points for European men and
women. The waist to hip ratio was calculated as waist
circumference divided by hip circumference, measured
to the nearest 0.5 cm. 
Statistical analyses  
Cox proportional hazard models were used to esti-
mate hazard ratios (HR) and 95% confidence intervals
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(CI). Age was the primary time variable in all models.
Age at entry was defined as the participants’ age at
recruitment and exit time was age at diagnosis of lym-
phoma, death, loss to follow-up or censoring at the end
of the follow-up period, whichever came first. A likeli-
hood ratio test was carried out to check for interactions
by including a cross-product term for gender and dia-
betes. Models were stratified by study Center and age
at EPIC study recruitment in 1-year categories, in order
to control for differences in questionnaire design, fol-
low-up procedures, and other center effects. We
obtained crude risk estimates of NHL for the following
potential confounders: physical activity, smoking sta-
tus, alcohol intake, level of education, medical history
of hyperlipidemia, hypertension, as well as anthropo-
metric measurements including height, weight, BMI,
waist to hip ratio, and waist circumference. To calcu-
late p values for trends across quintiles of anthropomet-
ric variables and categories of socio-demographic vari-
ables, participants were assigned a score according to
their quintile or category which was entered as a con-
tinuous term in the Cox regression models. Participants
with missing responses for a specific variable were
excluded from a given analysis. A covariate was consid-
ered a confounder if there was at least a 10% change in
the risk estimate for NHL and its subtypes when mod-
els were compared with and without the covariate
term. In addition, likelihood ratio tests were carried out
to check for confounders. Inclusion of any of the
adjustment variables did not alter risk estimates appre-
ciably and were not included in the final Cox model.
However, we also present risk estimates corrected for
BMI and smoking status.  
We confirmed the proportional hazards assumption
for diabetes status in relation to NHL using the likeli-
hood ratio test, comparing models with and without
product terms for diabetes and follow-up time (years).
All statistical tests were two-sided, and a p value < 0.05
was considered statistically significant. Analyses were
performed using Stata version 9.2. 
Results
We analyzed the association between self-reported
diabetes and the risk of NHL and MM and individual
lymphoma subtypes, separately for men and women.
Overall, 139,431 men and 254,046 women were fol-
lowed-up for an average of 8.5 years (Table 1). Of the
1,213 NHL cases, there were 1,079 cases of B-NHL and
43 of T-NHL. The most frequent subtypes of B-NHL
were B-CLL (n=224), diffuse large B-cell lymphoma
(n=152) and follicular lymphoma (n=138); 91 NHL
cases and 166 cases of B-NHL could not be further spec-
ified. 
The characteristics of the EPIC participants were
compared at baseline for men and women separately
(Table 2). Among cases with NHL and MM, the preva-
lence of diabetes was 5.39% and 2.10% for men and
women, respectively. The average age at diagnosis of
Table 1. Frequency of non-Hodgkin’s lymphoma (including multiple myeloma) subtypes and diabetes status by country among 139,431
men and 254,046 women in the EPIC study.
Cohort size Person-years NHL cases Diabetes cases
Men Women Men Women Men Women Men Women
Italy 13,999 30,458 120,532 262,606 51 74 313 633
Spain 15,116 24,809 156,203 244,699 49 51 875 1,114
UK 22,337 48,463 190,444 411,510 103 127 555 636
Netherlands 9,766 26,411 81,710 233,466 14 75 122 563
Greece 10,586 14,981 72,944 109,229 22 11 751 991
Germany 21,567 27,896 178,231 231,920 74 42 1183 792
Sweden 21,171 24,889 222,314 261,261 144 113 595 445
Denmark 24,889 27,557 188,589 212,652 137 94 717 432
Norway − 28,582 − 172,920 − 32 − 422
Total 139,431 254,046 1,212,292 2,140,266 594 619 5,111 6,028
NHL subgroups B-NHL subgroups
B-NHL T-NHL NHL nos DLBCL FL BCLL MM Other B nos
Italy 112 9 4 14 23 17 27 28 12
Spain 92 5 3 18 15 22 21 16 5
UK 202 6 22 25 25 35 53 34 36
Netherlands 83 4 2 17 16 15 20 10 9
Greece 31 1 1 4 3 9 7 3 6
Germany 104 5 7 9 13 23 33 16 15
Sweden 212 4 41 15 14 39 74 20 54
Denmark 213 7 11 46 24 61 43 27 19
Norway 30 2 0 4 5 3 3 7 10
Total 1,079 43 91 152 138 224 281 161 166
NHL nos: non-Hodgkin’s lymphoma not specified; DLBCL: diffuse large B-cell lymphoma (incl. Burkitt); FL: follicular lymphoma (all grades);  BCLL: B-cell chronic
lymphatic leukemia (incl. SLL, PLL); MM = Multiple myeloma/plasmacytoma; B nos: B-cell lymphomas not specified; Other: other subtypes incl. BALL (B-cell acute
lymphatic leukemia incl. ALL), LPL (lymphoplasmocytic lymphoma/Waldenström’s disease), ML (marginal zone B-cell lymphoma), and BO (B-cell lymphoma, other). 
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diabetes was 48.8 years and 47.3 years for men and
women, respectively. Use of insulin treatment for dia-
betes, among cases, was reported by 28.6% of the men
and 22.2% of the women.
Overall NHL risk 
There was no statistically significant association
between self-reported diabetes and overall NHL and
MM risk in men (HR: 1.28, 95% CI: 0.89– 1.84), in
women (HR: 0.71, 95% CI: 0.41–1.24), or in men and
women combined (HR: 1.09, 95% CI: 0.80– 1.47)
(Table 3). The interaction term for diabetes and gender
was of borderline statistical significance (p=0.06). In
order to reduce misclassification between type 1 and
type 2 diabetes, we excluded participants diagnosed
with diabetes before 30 years of age (n=886), as they
were assumed to be type 1 diabetics, but the risk esti-
mates did not change materially in men or in women
(HR: 1.29, 95% CI: 0.90–1.87; HR: 0.64, 95% CI: 0.35 –
1.17, respectively). The results did not change after
exclusion of cases of NHL and MM occuring within 1
or 2 years of the diagnosis of diabetes (data not shown). 
We investigated the association between NHL and
MM and insulin treatment. Among men, compared to
non-diabetics (used as the reference group), diabetics
not treated with insulin were at higher risk (HR: 1.48,
95% CI: 0.94 – 2.36) than those who were treated with
insulin (HR: 1.05, 95% CI: 0.52–2.14). Among women,
the risk of NHL and MM fell from 0.73 (0.34–1.56)
among diabetics not receiving insulin treatment to 0.36
(0.1–1.44) among those who used insulin, compared to
non-diabetics. However, information for the duration
of treatment was not available and therefore analyses
could not be carried out to evaluate the long-term and
independent effect of insulin treatment.
Risk of lymphoma subtypes 
Among the subtypes, we did not observe an associa-
tion between diabetes and overall B-NHL, although
hazard ratios were slightly elevated for men (Table 4).
We observed a statistically positive association
between diabetes and the risk of B-CLL in men (HR:
2.0, 95% CI: 1.04–3.86), but not in women (HR: 1.07,
95% CI: 0.33–3.43). Among other B-NHL subtypes,
increased risks were generally observed for diffuse
large B-cell lymphoma, follicular lymphoma and MM
among men, although these increases did not reach sta-
tistical significance. In women, non-significant reduced
risks were observed for diffuse large B-cell lymphoma
and follicular lymphoma. There was no statistically sig-
nificant relationship between diabetes and risk of T-
NHL in men or women (Table 4). 
Discussion 
This large prospective study did not provide evidence
for a role of self-reported diabetes in the etiology of
overall NHL and MM. An increased risk for a major B-
cell lymphoma subtype, B-CLL, was observed among
men, but not women.
Our study exploring the relationship between a per-
sonal history of diabetes and risk of NHL and MM in
Europe has some important merits. A major strength
includes the prospective nature of the study, which
included a large number of participants from the gener-
al population. NHL cases were histologically confirmed
primary incident cancers, systematically classified
according to the WHO classification of tumors of
hematopoietic and lymphoid tissue, an internationally
recognized classification scheme. Histological confir-
mation also allowed us to investigate various subtypes
of NHL, which is important because of possible etio-
logical heterogeneity among them. Other strengths of
the study include a comprehensive follow-up of the
cohort, an extensive evaluation of confounding factors,
such as anthropometric and socio-demographic vari-
ables, and use of a validated protocol to assess body fat
distribution. A large range of lifestyle risk factors were
assessed, which enabled us to evaluate confounding by
known and potential risk factors. 
In our study, diabetes was self-reported, raising the
question of misclassification of diabetes status.
However, we do not think this was a major concern
because type 2 diabetes is a condition that patients are
generally aware of and evaluations of the validity of
self-reported diabetes status have suggested good to
very good agreement between self-reports and medical
records.17 No distinction was made between the type of
diabetes diagnosed, whether type 1 or type 2, or
according to the severity of the disease. Type 1 diabetes
does not involve hyperinsulinemia and has not been
considered in the etiology of NHL. As mentioned
before, we carried out separate analyses excluding par-
ticipants aged <30 years at the time of their diagnosis
of diabetes (n=886) and the risk estimates did not
change appreciably. We, therefore, think that it is
unlikely that biases occurred in this regard.
Associations may change with a longer follow-up peri-
od. A case-control study by Vineis et al., which took
into consideration different latency periods between
the diagnoses of diabetes and NHL, did, however,
show that NHL risk was not associated with a longer
duration of diabetes.26 Finally, inferences from risk esti-
mates for specific NHL subtypes may have been ham-
pered by small numbers. 
Risk of lymphoma overall
Diabetes has not been consistently associated with a
risk of NHL in previous studies. This study concurs
with the results of seven cohort and case-control stud-
ies that have investigated this association. Ragozzino et
al.21 initially reported increased risk for lymphoma
among diabetics in a prospective cohort of residents in
Minnesota, USA, but subsequent reanalyses36 found no
association. Adami et al.,16 in another cohort study with
a long follow-up of 26 years, found no association
between diabetes and hematopoietic cancer among
men or women, calculated after a 1-year latency. On
the other hand, a cohort study11 of just over 2,000
Danish men and women found an increased risk of
developing tumors of the lymphatic and hematopoiet-
ic tissues in diabetic patients. Five population and hos-
pital-based case-control studies reported no or inverse
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Table 2. Baseline characteristics of 139,431 male and 254,046 female participants in EPIC by diabetes status.
Men Women
Diabetes No Diabetes Diabetes No Diabetes
N=5,111 N=134,320 N=6,028 N=248,018
N % N % N % N %
Age (years) 58.0 51.9 56.8 50.1
Body mass index (kg/m2) 28.2 26.4 29.3 25.3
Waist-to-hip ratio 0.972 0.937 0.855 0.792
Hypertension 1,968 44.07 24,340 20.95 2500 50.85 37,456 17.83
Hyperlipidemia 1,783 42.45 22,903 22.10 1917 39.15 25,091 13.70
Total physical activity
Inactive 1632 33.39 21,800 18.24 2619 48.02 51,994 25.46
Moderately inactive 1437 29.40 37208 31.13 1065 29.43 70,708 34.62
Moderately active 992 20.30 29696 24.84 709 13.00 44,374 21.73
Active 826 16.90 30827 25.79 521 9.55 37,153 18.19
Smoking status
Life-long non-smoker 1236 24.26 41,247 30.98 3764 62.74 123,820 50.48
Current cigarettes <15/day 430 8.44 12,588 9.45 447 7.45 30,387 12.39
Current cigarettes 15-24/day 462 9.07 12,649 9.50 329 5.48 18,007 7.34
Current cigarettes 25+/day 294 5.77 6,967 5.23 98 1.63 4,161 1.70
Ex-smoker <10 years 846 16.60 17,430 13.09 456 7.60 22,602 9.21
Ex-smoker 10+ years 1418 27.83 28,834 21.66 673 11.22 33,088 13.49
Other smoking 409 8.03 13,431 10.09 232 3.87 13,214 5.39
Alcohol intake, g/day
No ethanol intake 652 12.76 8,401 6.25 2162 35.87 41,409 16.70
<5 g/day 1249 24.44 28783 21.43 2381 39.50 101,689 41.00
5-14 g/day 1138 22.27 35194 26.20 963 15.98 67,562 27.24
15-29 g/day 897 17.55 27920 20.79 333 5.52 24,018 9.68
30+ g/day 1175 22.99 34022 25.33 189 3.14 13,340 5.38
Education
No degree/primary school 2394 48.38 40,004 30.68 3233 57.24 72,330 30.31
Technical/professional school 1068 21.58 32,966 25.28 1144 20.25 67121 28.13
Secondary school 514 10.39 21,833 16.74 743 13.16 50471 21.15
University degree 972 19.64 35,609 27.31 528 9.35 48690 20.41
Body mass index
Underweight/ normal 1108 21.68 49,094 36.55 1372 22.76 134577 54.26
Overweight 2460 48.13 65,470 48.74 2129 35.32 78,367 31.60
Obese 1543 30.19 19,756 14.71 2527 41.92 35,074 14.14
Table 3. Relative risk (HR) with 95% confidence intervals (CI) for the development of non-Hodgkin’s lymphoma (including MM) among
139,431 men and 253,427 women in the EPIC study.
With NHL Without NHL HRa (95% CI) HRb (95% CI)
N=1,213 N=392,264
Type 2 diabetes N % N %
Men 32 5.39 5,079 3.66 1.28 (0.89–1.84) 1.26(0.88–1.81)
Women 13 2.10 6,015 2.37 0.71 (0.41–1.24) 0.72 (0.41–1.26)
Men and women combined 45 3.71 11,094 2.83 1.09 (0.8–1.47) 1.07 (0.80–1.45)
aResults stratified by age at recruitment and study center. bResults stratified by age at recruitment and study center  and adjusted for tobacco smoking and BMI at baseline. 
Table 4. Relative risk (HR) and 95% confidence intervals (CI) for non-Hodgkin’s lymphoma subtypes among 139,431 men and 253,427
women in the EPIC study.
T-NHL B-NHL DLBCL FL BCLL MM
Type 2 diabetes Ncases HRa Ncases HRa Ncases HRa Ncases HRa Ncases HRa Ncases HRa
(95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI)
Men 27 0.77 521 1.37 72 1.70 53 1.52 125 2.0 145 1.27
(0.1–5.76) (0.94 - 1.99) (0.67 – 4.3) (0.46 – 5.0) (1.04 – 3.86) (0.61 – 2.63)
Women 16 − 558 0.72 80 0.46 85 0.74 99 1.07 136 0.64
(0.41–1.29) (0.6–3.36) (0.18–3.0) (0.33–3.43) (0.20–2.06)
aResults stratified by age at recruitment and study center. DLBCL, diffuse large B-cell lymphoma. FL, follicular lymphoma.
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associations.26-29 Although results are contradictory, the
bulk of evidence published to date suggests no associa-
tion of diabetes with overall NHL risk. 
Insulin treatment   
Use of insulin treatment has been rising along with
the prevalence of diabetes. In our study, we found a
weak inverse relation between insulin treatment and
risk of developing NHL, which is consistent with the
findings of studies by Fortuny et al.23 and Zhang et al.37
It has been suggested that this effect may be related to
continuous stimulation of the immune system by
insulin,23 which is chronically inoculated several times
a day. In such a case, longer duration of insulin use
should be related to greater protection from NHL,
because of stronger immune system stimulation by
older insulins of animal origin. However, we could not
reach any conclusions about use of insulin and lym-
phoma risk from the data in our study. Treatment
effects could be confounded by the duration of the dis-
ease and our findings may be due to chance or sparse
data. 
Lymphoma subtypes   
In our analyses, diabetes was associated with the sub-
sequent risk of B-CLL in men. We also found suggestive
positive associations between diabetes and the risk of
overall B-cell lymphomas, diffuse large B-cell and follic-
ular lymphomas and MM among men, but these results
were not statistically significant. It is not clear why such
associations were stronger for men than for women.
Among previous studies, type 2 diabetes was observed
to increase the risk of MM,23 but not B-CLL.
B-CLL is a neoplastic disease characterized by the
accumulation of small, mature-appearing lymphocytes
in blood, bone marrow, and lymphoid tissues.38 A fam-
ily history of CLL or other hematolymphoproliferative
cancers, and exposure to some environmental and
occupational factors, such as pesticides and ionizing
radiation, have been suggested as risk factors for CLL.
To our knowledge, the potential role of type 2 diabetes
has not been investigated specifically in the etiology of
B-CLL, but the phenomenon of autoimmunity has been
inconsistently linked to B-CLL in previous epidemio-
logiced studies,10,38,39 implying that there is some evi-
dence of familial aggregation patterns for CLL.  In sup-
port of a role of autoimmunity in type 2 diabetes,
Pietropaolo et al. reported the presence of islet cell
autoimmunity associated with an impairment of the
acute-phase insulin secretion in type 2 diabetic
patients.12 It has been suggested that cytokines such as
tumor necrosis factor-α might contribute to the devel-
opment of insulin resistance in type 2 diabetes by
inhibiting the tyrosine kinase activity of insulin recep-
tors, and that interleukins may promote an impairment
of insulin secretion in pancreatic β-cells.12
It is difficult to tease out a possible causal sequence
between type 2 diabetes and B-CLL. On the one hand,
a possible biological link may be mediated through
cytokine activity. There is substantial evidence suggest-
ing that excess fat activates the production of
cytokines, which may induce insulin resistance.
Interleukin-6, a pleiotropic cytokine expressed by a
variety of different cell types, including lymphoid and
endothelial cells, fibroblasts, skeletal muscle, and adi-
pose tissue, is involved in the regulation of energy bal-
ance.40 Circulating levels of interleukin-6 are raised in
insulin-resistant states, such as obesity, which has also
been linked with an increased risk of NHL.41 A com-
mon polymorphism in the interleukin-6 gene has been
associated with insulin resistance42 and may predict the
development of type 2 diabetes. Interleukin-6 has been
implicated in the neoplastic process of a variety of
malignancies, including prostate43 and pancreatic can-
cer.44 Because cytokines control lymphoid cell develop-
ment and differentiation, cytokine activity might influ-
ence the pathogenesis of NHL. Interleukin-6 promotes
normal plasma cell development and proliferation of
myeloma cells in culture, and has been associated with
an increased risk of plasma cell neoplasms.45 Cozen et
al. found that the variant allele of the interleukin pro-
moter single nucleotide polymorphism -572 was asso-
ciated with a 2-fold increased risk of plasma cell neo-
plasms, compared to the risk in family and population
controls.45 Increased concentrations of interleukin-6
and interleukin-12 were also found in blood plasma,
culture supernatant and isolated and broken lympho-
cytes from patients with B-CLL.46
On the other hand, B-CLL patients have been
observed to develop autoimmune diseases, frequently,
implying immune dysregulation.47 It has been postulat-
ed that the association of certain autoimmune diseases
with B-CLL reflects reverse causality due to undetected
cases of CLL manifesting in patients who express
autoimmune disorders as their first symptom. This
hypothesis is based on the rationale that during the
course of B-CLL, some degree of activation of B cells
may lead to an autoimmune disorder in CLL. The
source of the autoantibodies is either uncontrolled pro-
duction of malignant B cells or disturbances of residual
normal B cells involved in the immune system.48
We, however, hypothesize that diabetes may not
play a causal role in the etiology of B-CLL, but that the
two diseases may share a common pathway in the
early stages of development, or may have common
genetic or environmental etiological factors. Common
factors, such as obesity, diet, physical activity and other
lifestyle habits, may play a role in the development of
both B-CLL and type 2 diabetes. Obesity is closely
related to diabetes in terms of etiology, which is best
demonstrated by the increase in plasma concentrations
of inflammatory mediators, such as C-reactive protein
and interleukin-6, in both conditions. In such a case,
inflammatory conditions may be markers of impaired
immunological states and an indicator of the risk,
rather than a cause.  Studies on markers of inflamma-
tion and adipose tissue biology will help us to under-
stand the pathogenesis and the consequences of these
conditions better.  
In conclusion, we found no evidence that type 2 dia-
betes plays a causal role in the development of NHL
overall. The positive association of self-reported dia-
betes with B-CLL in men should be interpreted with
caution, because of the small numbers involved. Given
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the large size of the cohort and the prospective nature
of the study design, it is unlikely that the study had
major biases. In future, focusing on lifestyle factors,
such as diet and physical activity, may be of help to elu-
cidate the etiology of lymphomas. In addition, research
on biomarkers focusing on insulin, the family of
insulin-like growth factors, and blood glucose levels
should also help to clarify whether a biological mecha-
nism links the metabolic abnormalities, characterized
by type 2 diabetes, to carcinogenesis. 
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